Expression of deleted in liver cancer 2 in colorectal cancer and its correlation with clinicopathological parameters

  • Authors:
    • Kai Gao
    • Xiaorong Li
    • Gui Hu
    • Kaiyan Yang
    • Buning Tian
    • Yi Zhang
  • View Affiliations

  • Published online on: August 6, 2012     https://doi.org/10.3892/ol.2012.854
  • Pages: 988-992
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Deleted in liver cancer 2 (DLC2) has been identified as a tumor suppressor gene. DLC2 is closely related to deleted in liver cancer 1 (DLC1) and is located at chromosome 13q12.3. The expression of DLC2 mRNA has been found in a wide range of cancers, including colorectal cancer (CRC). However, there are no available data on the expression status of DLC2 in Chinese patients with CRC and its correlation with clinicopathological parameters. The aim of this study was to investigate the expression levels of DLC2 mRNA and protein in Chinese patients with CRC and the correlation between DLC2 expression and clinicopathological parameters. To this end, real-time PCR, western blotting and immunohistochemistry were employed to detect DLC2 mRNA and protein expression in CRC and pericarcinomatous intestinal tissue (PCIT) specimens, which were obtained from 102 Chinese CRC patients who underwent surgical resection between October 2010 and February 2012. We also analyzed the correlations between DLC2 expression and the clinicopathological parameters of CRC patients. Our results showed that CRC tissues had significantly lower levels of DLC2 mRNA compared with PCITs (P<0.05); however, the protein expression levels were not significantly different between CRCs and PCITs. The expression levels of DLC2 mRNA and protein were significantly correlated with lymph node metastasis and tumor TNM stage. Additionally, DLC2 mRNA expression levels were also correlated with tumor histopathological degree (P<0.05). Collectively, our results suggest that the downregulated expression of DLC2 participates in CRC carcinogenesis, invasion and lymph node metastasis. Furthermore, our results imply that DLC2 is be a potential prognostic marker for CRC patients.

Introduction

Colorectal cancer (CRC) is one of the most common malignant tumors, with 1,200,000 new cases and 608,700 mortalities worldwide annually (1); furthermore, it is the fourth leading cause of cancer-related mortality in China. In recent decades, the incidence of CRC has increased. Despite surgical resection coupled with systemic chemotherapy, approximately half of newly diagnosed CRC patients are likely to succumb to the disease due to tumor recurrence and metastasis (2). The molecular mechanism leading to the development, local invasion and distal metastasis of CRC remains unclear. Thus, the delineation of the mechanisms for colorectal carcinogenesis is of importance, as it may provide novel strategies for diagnosis and prognosis.

Deleted in liver cancer 2 (DLC2), also called STARD 13, has been identified as a tumor suppressor gene and is closely related to deleted in liver cancer 1 (DLC1). DLC2 is located at chromosome 13q12.3 (3). DLC1 and DLC2 proteins share 51% identity and 64% similarity at the level of their amino acid sequences. DLC2 protein contains multiple domains, including a sterile α motif (SAM), a RhoGAP and a lipid-binding StAR-related lipid-transfer (START) domain. Previous studies have shown that DLC2 suppressed cytoskeleton reorganization, cell growth, cell migration and transformation in hepatocellular carcinoma (HCC) (4); the START domain of DLC2 has been reported to be involved in mitochondrial localization in hepatoma cells (5) and our previous study indicated that patients with DLC2 underexpression showed a significantly poorer prognosis than those with high DLC2 expression in HCC (6). To date, all studies examining DLC2 expression and its suppressed function have been conducted on HCC. However, DLC2 mRNA has been found to be downregulated in a wide range of cancers, including CRC (7), but there have been no available data on the expression levels of DLC2 mRNA and protein in clinical CRC, especially in Chinese patients.

Therefore, in this study we examined the DLC2 mRNA and protein expression in Chinese patients with CRC and evaluated the correlations between DLC2 expression levels and clinicopathological parameters of CRC.

Materials and methods

Tissue specimens

The study protocol was approved by the Ethics Committee of the Central South University (CSU). Fresh samples of CRC tissues and pericarcinomatous intestine tissues (PCITs, 2.0 cm away from the carcinoma) were obtained from 102 (66 males and 36 females) Chinese patients with primary cancer who underwent surgery at The Third Affiliated Hospital of Central South University between Octorber 2010 and February 2012. Each specimen was divided into two parts; one was immediately frozen in liquid nitrogen and stored at −80°C for real-time PCR and western blot analysis, the other was fixed in 4% paraformaldehyde for immunohistochemistry. The median age of the patients was 55.43 years, ranging from 26 to 78 years. All specimens obtained from surgical resection were confirmed by pathological examination. Written informed consent was obtained from each patient prior to the study.

Real-time PCR

Total RNA was extracted from specimens using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. Aliquots of 5 μg RNA from each sample were reverse transcribed. Quantitative analysis of DLC2 mRNA expression using the SYBR Green method was performed using the ABI 7300 real-time PCR system. The sequences of the primers were as follows: DLC2 5′-GTCAATGGGCTCCAAGAGGTAG-3′ (forward) and 5′-TGATTAGGAGATGGAAAGGTGGA-3′ (reverse); GAPDH (endogenous control): 5′-CTGCACCACCAACTG CTTAG-3′ (forward); 5′-AGGTCCACCACTGACACGTT-3′ (reverse). A 25-μl reaction mixture containing 1 μl cDNA template, 12.5 μl SYBR Master mix and 0.20 μl of each primer was amplified using the following thermal parameters: denaturing at 95˚C for 10 min and 45 cycles of the amplification step (denaturation at 95˚C for 15 sec, annealing and extension at 60˚C for 1 min). All amplification reactions were performed in triplicate and the averages of the threshold cycles (Cts) were used to interpolate curves using 7300 System SDS software. The results were expressed as the ratio of DLC2 mRNA to GAPDH mRNA, and the results of each sample was compared against one control sample to eliminate the differences between the PCR plates.

Western blot analysis

Protein was extracted from the specimens using the fierce RIPA lysis buffer (Beyotime Biotech, Jiangsu, China) following the manufacturer's instructions. Briefly, an equal amount (35 μg) of the total protein was separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE; Beyotime Biotech) and then transferred onto a polyvinylidene difluoride (PVDF; Pall, NY, USA) membrane using standard procedures. The membranes were immunoblotted with antibodies against DLC2 (rabbit polyclonal antibody; Sigma, St. Louis, MO, USA), followed by a horseradish peroxidase-conjugated secondary antibody. The washes were repeated before the membranes were detected using ECL system (KPL Biosciences, Gaithesburg, MD, USA). Band intensities were analyzed densitometrically using the Image J software.

Immunohistochemistry

All the specimens were immunohistochemically evaluated. In brief, tissue sections of 3-μm thickness were cut and baked at 60˚C, deparaffinized in xylene and rehydrated through graded ethanol. Next, 3% hydrogen peroxide and methanol were applied to block the endogenous peroxidases and sections were subjected to heat-induced antigen retrieval in 0.01 M citrate buffer (pH=6.0). The samples were incubated overnight with primary antibodies against DLC2 at a 1:400 dilution (rabbit polyclonal antibody; Sigma). Then, the samples were treated with MaxVision TM HRP-Polymer anti-Mouse/Rabbit IHC kit (KIT-5020, MaxVision, Shenzen, China) and 3,3′-diaminobenzidine tetrahydrochloride (DAB). Counterstaining was performed with 0.5% hematoxylin.

Statistical analysis

Statistical analysis was performed using SPSS software (version 17.0; SPSS, Inc., Chicago, IL, USA). Data are expressed as mean ± SD and, for clarity, as mean ± SEM in figures. The Student's t-test was used to analyze the correlation betwen the expression of DLC2 in CRC and PCIT. The non-parametric Mann-Whitney U test was used to analyze the correlations between the expression of DLC2 and clinicopathological variables. P<0.05 was considered to indicate a statistically significant result.

Results

Expression of DLC2 mRNA in CRC and PCIT

The expression of DLC2 mRNA was detected in all CRC and PCIT specimens using real-time PCR. The relative expression of DLC2 mRNA in CRC and PCIT was 29.16±5.36 and 65.87±17.05, respectively. The mRNA expression in CRC tissues was significantly lower than that in PCIT (P=0.037; Fig. 1).

Expression of DLC2 protein in CRC and PCIT

The protein expression was detected in all CRC and PCIT specimens using western blotting. The relative expression of DLC2 protein in CRC and PCIT was 2.29±0.61 and 1.66±0.65, respectively. There was no significant difference between CRC and PCIT. In addition, to identify the DLC2 protein expression status, immunohistochemical staining was also employed. The result was consistent that of the western blot analysis (Fig. 2).

Correlations between DLC2 expression levels and clinicopathological parameters of CRC

The distribution pattern of DLC2 was determined by dividing the expression levels of DLC2 mRNA and protein in the subgroups by clinicopathological parameters. A significant difference was found between DLC2 expression levels in CRC with or without lymph node metastasis (P= 0.021 and 0.028, respectively); both DLC2 mRNA and protein expression levels in CRC with lymph node metastasis were lower than those in CRC cases without lymph node metastasis (Figs. 3A and 4A). DLC2 mRNA and protein expression levels of CRC of tumor TNM stage III and IV also showed lower expression levels than in CRC cases of stage I and II (P=0.020 and 0.026, respectively; Figs. 3B and 4B). In addition, the expression status of DLC2 mRNA was also correlated with tumor histopathological degree; poorly differentiated CRC cases had a lower expression level of DLC2 than well- and moderately differentiated CRC (P= 0.004; Fig. 5). However, there was no significant association between the expression levels of DLC2 and other clinicopathological parameters, including gender, age, tumor size, tumor site, depth of cancer invasion, distant metastasis and blood levels of carcinoembryonic antigen (CEA; Table I).

Table I

Correlation between expression levels of DLC2 and clinicopathological parameters.

Table I

Correlation between expression levels of DLC2 and clinicopathological parameters.

VariableNo. of patientsP-value
DLC2 mRNADLC2 protein
Gender0.4290.288
  Male66
  Female36
Age (years)0.6250.420
  <6060
  ≥6042
Tumor site0.5280.918
  Colon45
  Rectum57
Tumor size (cm)0.4570.425
  <5.052
  ≥5.050
Tumor depth0.8760.354
  Limited to muscular layer66
  Serosa and adjacent fat36
Lymph node metastasis0.021a0.028a
  Negative50
  Positive52
Distant metastasis0.3380.233
  Absent94
  Present8
Tumor TNM stage0.020a0.026a
  I and II49
  III and IV53
Tumor differentiation0.004a0.080
  Well-moderate76
  Poor26
CEA (ng/ml)0.9030.271
  ≥541
  <561

a P<0.05. DLC2, deleted in liver cancer 2; CEA, carcinoembryonic antigen.

Discussion

Although DLC2 has been identified as a tumor suppressor gene, the expression levels of DLC2 mRNA and protein, especially in clinical CRC of Chinese patients, have not been studied. The present study indicates that the expression level of DLC2 mRNA was significantly lower in CRC than in PCIT; however, the protein expression level of DLC2 was not significantly different in CRC compared with PCIT in Chinese patients. This difference between mRNA and protein may be due to post-transcriptional control. With regard to human neoplasia, Ullmannova and Popescu reported that the DLC2 mRNA level was downregulated in lung, ovarian, renal, breast, uterine, gastric, colon and rectal tumors and that the expression ratios of DLC2 in colon and rectal cancer were 46 and 61%, respectively (7). Our real-time PCR results showed that DLC2 mRNA was also underexpressed and the expression ratios of DLC2 mRNA were 70 and 62% in colon and rectal cancer, respectively. This result is higher than that reported by Ullmannova and Popescu; the reason for this difference may be differences between ethnicities. Also, the low expression of DLC2 has been confirmed to be involved in the invasion and migration of HCC cells (4). DLC2 protein has been reported to inhibit the activity of Raf-1-ERK1/2-p70S6K via its RhoGAP function, resulting in the suppression of cell growth (8). DLC2 has been found to modulate angiogenic responses in vascular endothelial cells by regulating cell attachment and migration (9). Consistent with previous studies, the present study showed that DLC2 mRNA was downregulated in CRC, which indicates that DLC2 participates in colorectal carcinogenesis and plays an important role in the invasion and metastasis of CRC.

To investigate how DLC2 affects colorectal carcinogenesis, we evaluated the correlations between DLC2 expression levels, including mRNA and protein, and clinicopathological parameters of CRC. Our results revealed that the expression levels of DLC2 mRNA and protein were frequently with lymph node metastasis and the DLC2 expression levels in CRC with lymph node metastasis were lower than those in CRC without lymph node metastasis. This result indicates that DLC2 is a tumor suppressor, whose downregulated expression stimulates the lymph node metastasis of CRC. This implies that DLC2 has a role in suppressing CRC lymph node metastasis. Our previous study showed that a lower expression level of DLC2 was associated with higher expression level of RhoA in HCC (6). In addition, other studies have shown that DLC2 exhibited its tumor suppressor functions by means of the inhibition of RhoA activity (4); a higher level expression of RhoA has been detected in several types of cancer, including bladder, testicular, ovarian, colon, breast and lung cancer (1013); Takami et al demonstrated that the activity of RhoA was correlated with lymph node metastasis in human CRC (14). Accordingly, we hypothesized that the downregulation of DLC2 and upregulation of RhoA may be essential in CRC progression, especially in the process of CRC lymph node metastasis. To confirm this hypothesis, investigations into the correlation between DLC2 and RhoA are anticipated.

Notably, in the present study, the mRNA and protein expression levels of DLC2 were also correlated with CRC tumor TNM stage. Our results revealed that the DLC2 mRNA and protein expression levels in CRC of TNM stages III and IV were lower than those in CRCs of stage I and II. This result implies that downregulated mRNA and protein expression levels of DLC2 were correlated with advanced stage of CRC. Additionally, the mRNA expression level was correlated with tumor histopathological degree of CRC. It is well known that the TNM staging system of tumors is the gold standard for evaluating prognosis in patients with CRC. It has been reported that the five-year survival rates of CRC patients who underwent surgical resections were 94.1, 80.2, 61.7 and 23.2% with tumors of TNM stages I to IV, respectively (15); additionally, low tumor histopathological differentiation was also associated with poor survival (16). Thus, it is reasonable to assume that the downregulated expression of DLC2 is correlated with a poor prognosis of CRC patients. To test this assumption, we intend to continue the follow-up of these patients in our further research.

To the best of our knowledge, this is the first study to report DLC2 mRNA and protein expression levels in Chinese CRC patients and the downregulated expression levels of DLC2 mRNA and protein are associated with lymph node metastasis and tumor TNM stage in CRC. The DLC2 mRNA expression level is also correlated with tumor histopathological degree. Although a number of diagnostic advances have been made, it remains difficult to accurately diagnose lymph nodes metastasis and assess the prognosis of CRC. In this study, we found that the downregulated expression levels of DLC2 mRNA and protein were correlated with lymph node metastasis and tumor TNM stage. Furthermore, the underexpression of DLC2 mRNA was also associated with tumor histopathological degree of CRC. Therefore, the present study demonstrates that DLC2 may not only participate in CRC carcinogenesis, invasion and lymph node metastasis, but may also be a potential indicator for the presence of lymph nodes metastasis in CRC and a prognostic marker for CRC patients.

Acknowledgements

This study was supported by the Planned Science and Technology Project of Hunan Province, China (no. 22010FJ3087) and the Chinese National Science Foundation (no. 81172298). We would like to thank Dr Ren Guo for assistance with experiments and manuscript reviewing and formatting.

References

1. 

A JemalF BrayMM CenterJ FerlayE WardD FormanGlobal cancer statisticsCA Cancer J Clin616990201110.3322/caac.20107

2. 

HJ WilkeE Van CutsemCurrent treatments and future perspectives in colorectal and gastric cancerAnn Oncol14Suppl 2ii49ii55200310.1093/annonc/mdg73012810459

3. 

YP ChingCM WongSF ChanDeleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinomaJ Biol Chem2781082410830200310.1074/jbc.M20831020012531887

4. 

TH LeungYP ChingJW YamDeleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activityProc Natl Acad Sci USA1021520715212200510.1073/pnas.050450110216217026

5. 

DC NgSF ChanKH KokMitochondrial targeting of growth suppressor protein DLC2 through the START domainFEBS Lett580191198200610.1016/j.febslet.2005.11.07316364308

6. 

L XiaorongW WeiQ LiyuanY KaiyanUnderexpression of deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinomaBMC Cancer8205200810.1186/1471-2407-8-20518651974

7. 

V UllmannovaNC PopescuExpression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumorsInt J Oncol2911271132200617016643

8. 

TH LeungJW YamLK ChanYP ChingIO NgDeleted in liver cancer 2 suppresses cell growth via the regulation of the Raf-1-ERK1/2-p70S6K signalling pathwayLiver Int3013151323201010.1111/j.1478-3231.2010.02307.x20629949

9. 

Y LinNT ChenYP ShihYC LiaoL XueSH LoDLC2 modulates angiogenic responses in vascular endothelial cells by regulating cell attachment and migrationOncogene2930103016201010.1038/onc.2010.5420208559

10. 

AB JaffeA HallRho GTPases in transformation and metastasisAdv Cancer Res845780200210.1016/S0065-230X(02)84003-911883532

11. 

T KamaiK AraiT TsujiiM HondaK YoshidaOverexpression of RhoA mRNA is associated with advanced stage in testicular germ cell tumourBJU Int87227231200110.1046/j.1464-410x.2001.02030.x11167647

12. 

G FritzI JustB KainaRho GTPases are over-expressed in human tumorsInt J Cancer81682687199910.1002/(SICI)1097-0215(19990531)81:5%3C682::AID-IJC2%3E3.0.CO;2-B10328216

13. 

T KamaiT TsujiiK AraiSignificant association of Rho/ROCK pathway with invasion and metastasis of bladder cancerClin Cancer Res926322641200312855641

14. 

Y TakamiM HigashiS KumagaiThe activity of RhoA is correlated with lymph node metastasis in human colorectal cancerDig Dis Sci53467473200810.1007/s10620-007-9887-017597401

15. 

Y LuoJ CuiC ChenClinical outcomes after surgical resection of colorectal cancer in 1,294 patientsHepatogastroenterology5913981402201122115801

16. 

S GillCL LoprinziDJ SargentPooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?J Clin Oncol2217971806200410.1200/JCO.2004.09.05915067028

Related Articles

Journal Cover

November 2012
Volume 4 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Gao K, Li X, Hu G, Yang K, Tian B and Zhang Y: Expression of deleted in liver cancer 2 in colorectal cancer and its correlation with clinicopathological parameters. Oncol Lett 4: 988-992, 2012
APA
Gao, K., Li, X., Hu, G., Yang, K., Tian, B., & Zhang, Y. (2012). Expression of deleted in liver cancer 2 in colorectal cancer and its correlation with clinicopathological parameters. Oncology Letters, 4, 988-992. https://doi.org/10.3892/ol.2012.854
MLA
Gao, K., Li, X., Hu, G., Yang, K., Tian, B., Zhang, Y."Expression of deleted in liver cancer 2 in colorectal cancer and its correlation with clinicopathological parameters". Oncology Letters 4.5 (2012): 988-992.
Chicago
Gao, K., Li, X., Hu, G., Yang, K., Tian, B., Zhang, Y."Expression of deleted in liver cancer 2 in colorectal cancer and its correlation with clinicopathological parameters". Oncology Letters 4, no. 5 (2012): 988-992. https://doi.org/10.3892/ol.2012.854